Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5298-5300

  Herzog, Cynthia E ^a,c   Holmes, Katherine A ^b   Tuschong, Laura M ^a   Ganapathi, Ram ^b   Zwelling, Leonard A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; ISOENZYME; MESSENGER RNA; TUMOR ANTIGEN;

ARTICLE; COMPLEX FORMATION; DNA PROTEIN COMPLEX; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE DOSAGE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTERCALATION COMPLEX; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL STRAIN HL 60; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NORTHERN BLOTTING; PHENOTYPE; SOUTHERN BLOTTING;

AMSACRINE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MUTATION; PHENOTYPE; RNA, MESSENGER;

EID: 0032222419     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Zwelling, L. A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., Parker, E., Silberman, L., Radcliffe, A., Beran, M., and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. J. Biol. Chem., 264: 16411-16420, 1989.
2. Davies, S. M., Robson, C. N., Davies, S. L., and Hickson, I. D. Nuclear topoisomerase 11 levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem., 263: 17724-17729, 1988.
3. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28: 8154-8160, 1989.
4. Jenkins, J. R., Ayton, P., Jones, T., Davies, S. L., Simmons, D. L., Harris, A. L., Sheer, D., and Hickson, I. D. Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res., 20: 5587-5592, 1992.
5. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 Cells. Cell Growth Differ., 2: 209-214, 1991.
6. 4. Br. J. Cancer, 74: 1869-1876, 1996.
7. Dereuddre, S., Delaporte, C., and Jacquemin-Sablon, A. Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res., 57: 4301-4308, 1997.
8. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F. D., and Zwelling, L. A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res., 51: 4729-4731, 1991.
9. Austin, C. A., Sng, J., Patel, S., and Fisher, L. M. Novel HeLa topoisomerase II is the II β isoform: complete coding sequence and homology with other type II topoisomerases. Biochim. Biophys. Acta, 1772: 283-291, 1993.
10. Chung, T. D. Y., Drake, F. H., Tan, K. B., Per, S. R., and Crooke, S. T. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. USA, 86: 9431-9435, 1989.
11. Houlbrook, S., Addison, C. M., Davies, S. L., Carmichael, J., Stratford, I. J., Harris, A. L., and Hickson, I. D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer, 72: 1454-1461, 1995.
12. Ganapathi, R., Zwelling, L., Constantinou, A., Ford, J., and Grabowski, D. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biochem. Biophys. Res. Comm., 192: 1274-1280, 1993.
13. Chang, J. Y., Dethlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y. C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
14. Negri, C., Scovassi, A. I., Braghetti, A., Guano, F., and Astaldi Ricotti, G. C. B. DNA topoisomerase IIβ: stability and distribution in different animal cells in comparison to DNA topoisomerase I and IIα. Exp. Cell Res., 206: 128-133, 1993.
15. Turley, H., Comley, M., Houlbrook, S., Nozaki, N., Kikuchi, T., Hickson, I. D., Gatter, K., and Harris, A. L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer, 75: 1340-1346, 1997.
16. Wasserman, R. A., and Wang, J. C. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res., 54: 1795-1800, 1994.
17. Biersack, H., Jensen, S., Gromova, I., Nielson, I. S., Westergaard, O., and Andersen, A. H. Active heterodimers are formed from human DNA topoisomerase IIα and IIβ isoforms. Proc. Natl. Acad. Sci. USA, 93: 8288-8293, 1996.
18. Zwelling, L. A., Mayes, J., Hinds, M., Chan, D., Altschuler, E., Carroll, B., Parker, E., Deisseroth, K., Radcliffe, A., Seligman, M., Li, L., and Farquhar, D. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions. Biochemistry, 30: 4048-4055, 1991.
19. Jensen, S., Redwood, C. S., Jenkins, J. R., Andersen, A. H., and Hickson, I. D. Human DNA topoisomerase IIα and IIβ can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol. & Gen. Genet., 252: 79-86, 1996.